Insys Therapeutics, Inc.
INSY
INSY was delisted on the 18th of June, 2019.
154 hedge funds and large institutions have $1.15B invested in Insys Therapeutics, Inc. in 2015 Q4 according to their latest regulatory filings, with 32 funds opening new positions, 53 increasing their positions, 52 reducing their positions, and 23 closing their positions.
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
39% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 23
15% more capital invested
Capital invested by funds: $1B → $1.15B (+$147M)
6% more funds holding
Funds holding: 145 → 154 (+9)
6% more call options, than puts
Call options by funds: $17M | Put options by funds: $16.1M
2% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 52
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Scopia Capital Management
New York
|
+$114M |
| 2 |
GAM
Gotham Asset Management
New York
|
+$23M |
| 3 |
AA
Antipodean Advisors
New York
|
+$15.8M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$11.5M |
| 5 |
VM
Valinor Management
New York
|
+$8.16M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
-$25.3M |
| 2 |
Wells Fargo
San Francisco,
California
|
-$22.5M |
| 3 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
-$20.3M |
| 4 |
CCM
Consonance Capital Management
New York
|
-$19.1M |
| 5 |
GT
Glenmede Trust
Philadelphia,
Pennsylvania
|
-$17.7M |
INSY Hedge Fund Activity: Q4 2015 in Review
154 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Insys Therapeutics, Inc. (INSY) for Q4 2015, worth a combined $1.15B — up 15% from $1B a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new INSY positions and 23 closed out — a net gain of 9 holders — while 53 added to existing stakes and 52 trimmed.
The largest buyer was Scopia Capital Management, adding an estimated $114M. The largest seller was Invesco, cutting an estimated $25.3M.
- 154 institutional investors held Insys Therapeutics, Inc. (INSY) as of Q4 2015, up from 145 in Q3 2015.
- Funds reported $1.15B of Insys Therapeutics, Inc. stock for Q4 2015, up 15% quarter-over-quarter.
- 32 funds opened new Insys Therapeutics, Inc. positions in Q4 2015 and 23 closed out, a net change of +9 holders.
- The largest Insys Therapeutics, Inc. buyer in Q4 2015 was Scopia Capital Management, an estimated $114M added.
- The largest Insys Therapeutics, Inc. seller in Q4 2015 was Invesco, an estimated $25.3M sold.
Based on aggregated 13F filings for Q4 2015.